➤ Get the DrugPatentWatch Daily Briefing

Get Daily Updates on Generic Entry, Litigation, Biosimilars, and more …

Serving leading biopharmaceutical companies globally:

Express Scripts
Colorcon
McKesson
AstraZeneca
Dow
Mallinckrodt

Last Updated: January 23, 2021

DrugPatentWatch Database Preview

Drugs in Development Information for AG-120

➤ Get the DrugPatentWatch Daily Briefing
» See Plans and Pricing

« Back to Dashboard

What is the development status for investigational drug AG-120?

AG-120 is an investigational drug.

There have been 19 clinical trials for AG-120. The most recent clinical trial was a Phase 1 trial, which was initiated on June 1st 2017.

The most common disease conditions in clinical trials are Leukemia, Myeloid, Acute, Leukemia, Myeloid, and Myelodysplastic Syndromes. The leading clinical trial sponsors are Agios Pharmaceuticals, Inc., National Cancer Institute (NCI), and Celgene Corporation.

There are five US patents protecting this investigational drug and ninety-one international patents.

Recent Clinical Trials for AG-120
TitleSponsorPhase
Glasdegib-Based Treatment Combinations for the Treatment of Patients With Relapsed Acute Myeloid Leukemia Who Have Undergone Hematopoietic Cell TransplantationNational Cancer Institute (NCI)Phase 1
Glasdegib-Based Treatment Combinations for the Treatment of Patients With Relapsed Acute Myeloid Leukemia Who Have Undergone Hematopoietic Cell TransplantationCity of Hope Medical CenterPhase 1
CPX-351 and Ivosidenib for the Treatment of IDH1 Mutated Acute Myeloid Leukemia or High-Risk Myelodysplastic SyndromeNational Cancer Institute (NCI)Phase 2

See all AG-120 clinical trials

Clinical Trial Summary for AG-120

Top disease conditions for AG-120
Top clinical trial sponsors for AG-120

See all AG-120 clinical trials

US Patents for AG-120

Drugname Patent Number Patent Title Patent Assignee Estimated Expiration
AG-120   Start Trial Pharmaceutical compositions of therapeutically active compounds Agios Pharmaceuticals, Inc. (Cambridge, MA)   Start Trial
AG-120   Start Trial Methods and compositions for cell-proliferation-related disorders Agios Pharmaceuticals, Inc. (Cambridge, MA)   Start Trial
AG-120   Start Trial Therapeutically active compositions and their methods of use Agios Pharmaceuticals, Inc. (Cambridge, MA)   Start Trial
>Drugname >Patent Number >Patent Title >Patent Assignee >Estimated Expiration

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Express Scripts
Colorcon
McKesson
AstraZeneca
Dow
Mallinckrodt

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.